<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02347085</url>
  </required_header>
  <id_info>
    <org_study_id>PT003012</org_study_id>
    <nct_id>NCT02347085</nct_id>
  </id_info>
  <brief_title>24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI</brief_title>
  <official_title>A Randomized, Phase IIIb, Two-period, Two-treatment Double-blind, Multi-center, Crossover Study to Evaluate the 24-hour Lung Function Profile in Subjects With Moderate to Very Severe COPD After 4 Weeks of Treatment With PT003 and Placebo MDI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, Phase IIIb, Two-period, Two-treatment Double-blind, Multi-center, Crossover Study
      to Evaluate the 24-hour Lung Function Profile in Subjects with Moderate to Very Severe COPD
      after 4 Weeks of Treatment with PT003 and Placebo MDI
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 AUC0-24 on Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC)0-24 on Day 29</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC12-24 on Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>FEV1 AUC12-24 on Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-12 on Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>FEV1 AUC0-12 on Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in FEV1 on Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>Peak Change From Baseline in FEV1 following evening Dose on Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in FEV1 on Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>Peak Change From Baseline in FEV1 following the morning dose on Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Pre-Dose Trough FEV1 on Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>Morning Pre-Dose Trough FEV on Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Pre-Dose Trough FEV1 on Day 30</measure>
    <time_frame>Day 30</time_frame>
    <description>Morning Pre-Dose Trough FEV1 on Day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in Inspiratory Capacity (IC) Following the Evening Dose on Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>Peak Change from Baseline in Inspiratory Capacity (IC) following the evening dose on Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in IC Following the Morning Dose on Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>Peak Change from Baseline in IC following the morning dose on Day 29</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>GFF MDI (PT003)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MDI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFF MDI (PT003)</intervention_name>
    <arm_group_label>GFF MDI (PT003)</arm_group_label>
    <other_name>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo MDI</intervention_name>
    <arm_group_label>Placebo MDI</arm_group_label>
    <other_name>Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 40 years of age and no older than 80 at Screening

          -  Women of non-child bearing potential or negative serum pregnancy test at Screening,
             and agrees to acceptable contraceptive methods used consistently and correctly
             Screening until 14 days after final visit

          -  Subjects with an established clinical history of COPD as defined by the American
             Thoracic Society (ATS)/European Respiratory Society (ERS)

          -  Current or former smokers with a history of at least 10 pack-years of cigarette
             smoking

          -  Pre- and post-bronchodilator FEV1/FVC ratio of &lt;0.70

          -  Post-bronchodilator FEV1 must be &lt;80% predicted normal value, calculated using NHANES
             III reference equations, and the measured FEV1 must also be ≥750 mL if FEV1 &lt;30% of
             predicted normal value

        Exclusion Criteria:

          -  Significant diseases other than COPD, i.e., disease or condition which, in the opinion
             of the Investigator, may put the subject at risk because of participation in the study
             or may influence either the results of the study or the subject's ability to
             participate in the study

          -  Women who are pregnant or lactating

          -  Subjects, who in the opinion of the Investigator, have a current diagnosis of asthma

          -  Subjects who have been hospitalized due to poorly controlled COPD within 3 months
             prior to Screening or during the Screening Period

          -  Subjects who have poorly controlled COPD, defined as acute worsening of COPD that
             requires treatment with oral corticosteroids or antibiotics within 6 weeks prior to
             Screening or during the Screening Period

          -  Subjects who have clinically significant uncontrolled hypertension.

          -  Subjects who have cancer that has not been in complete remission for at least five
             years

          -  Subjects with abnormal liver function tests defined as AST, ALT, or total bilirubin
             ≥1.5 times upper limit of normal at Screening and on repeat testing

          -  Subjects with a diagnosis of angle closure glaucoma will be excluded, regardless of
             whether or not they have been treated. Subjects with a diagnosis of open angle
             glaucoma who have intraocular pressure controlled with medication(s) are eligible

          -  Subjects with symptomatic prostatic hypertrophy that is clinically significant in the
             opinion of the Investigator. Subjects with a trans-urethral resection of prostate
             (TURP) or full resection of the prostate within 6 months prior to Screening are
             excluded from the study

          -  Subjects with bladder neck obstruction or urinary retention that is clinically
             significant in the opinion of the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Reisner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pearl Therapeutics</affiliation>
  </overall_official>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2015</study_first_submitted>
  <study_first_submitted_qc>January 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2015</study_first_posted>
  <results_first_submitted>June 3, 2016</results_first_submitted>
  <results_first_submitted_qc>March 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2017</results_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 5 sites in the US from March 2015 to Jun 2015. The study was anticipated to run for approximately 6 months but not to expected to exceed 9 months.The study period was 11 to 17 weeks for each subject.</recruitment_details>
      <pre_assignment_details>Complete crossover study to assess the efficacy and safety of GFF MDI vs. Placebo MDI. Each subject received 28 days of study treatment in each assigned treatment, with a minimum 7 day washout period between each of the 2 periods. By-treatment sequence tabulations of the data were not pre-specified.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>All subjects randomized</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GFF MDI 14.4/9.6 µg</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo MDI</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The MITT Population was a subset of the ITT Population including the subjects who received treatment and had post-treatment efficacy data from both treatment periods.</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FEV1 AUC0-24 on Day 29</title>
        <description>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC)0-24 on Day 29</description>
        <time_frame>Day 29</time_frame>
        <population>Modified-Intent-to-Treat (MITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MD (PT003)</title>
            <description>GFF MDI 14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC0-24 on Day 29</title>
          <description>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC)0-24 on Day 29</description>
          <population>Modified-Intent-to-Treat (MITT) Population</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.166" lower_limit="0.110" upper_limit="0.222"/>
                    <measurement group_id="O2" value="-0.083" lower_limit="-0.143" upper_limit="-0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC12-24 on Day 29</title>
        <description>FEV1 AUC12-24 on Day 29</description>
        <time_frame>Day 29</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MD (PT003)</title>
            <description>GFF MDI 14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC12-24 on Day 29</title>
          <description>FEV1 AUC12-24 on Day 29</description>
          <population>MITT Population</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.115" lower_limit="0.055" upper_limit="0.175"/>
                    <measurement group_id="O2" value="-0.127" lower_limit="-0.191" upper_limit="-0.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC0-12 on Day 29</title>
        <description>FEV1 AUC0-12 on Day 29</description>
        <time_frame>Day 29</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MD (PT003)</title>
            <description>GFF MDI 14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC0-12 on Day 29</title>
          <description>FEV1 AUC0-12 on Day 29</description>
          <population>MITT Population</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.216" lower_limit="0.157" upper_limit="0.276"/>
                    <measurement group_id="O2" value="-0.039" lower_limit="-0.103" upper_limit="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in FEV1 on Day 29</title>
        <description>Peak Change From Baseline in FEV1 following evening Dose on Day 29</description>
        <time_frame>Day 29</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MD (PT003)</title>
            <description>GFF MDI 14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in FEV1 on Day 29</title>
          <description>Peak Change From Baseline in FEV1 following evening Dose on Day 29</description>
          <population>MITT Population</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.344" lower_limit="0.275" upper_limit="0.412"/>
                    <measurement group_id="O2" value="0.050" lower_limit="-0.023" upper_limit="0.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in FEV1 on Day 29</title>
        <description>Peak Change From Baseline in FEV1 following the morning dose on Day 29</description>
        <time_frame>Day 29</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MD (PT003)</title>
            <description>GFF MDI 14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in FEV1 on Day 29</title>
          <description>Peak Change From Baseline in FEV1 following the morning dose on Day 29</description>
          <population>MITT Population</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.410" lower_limit="0.338" upper_limit="0.482"/>
                    <measurement group_id="O2" value="0.134" lower_limit="0.058" upper_limit="0.209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Pre-Dose Trough FEV1 on Day 29</title>
        <description>Morning Pre-Dose Trough FEV on Day 29</description>
        <time_frame>Day 29</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MD (PT003)</title>
            <description>GFF MDI 14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Pre-Dose Trough FEV1 on Day 29</title>
          <description>Morning Pre-Dose Trough FEV on Day 29</description>
          <population>MITT Population</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.130" lower_limit="0.086" upper_limit="0.173"/>
                    <measurement group_id="O2" value="-0.012" lower_limit="-0.058" upper_limit="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Pre-Dose Trough FEV1 on Day 30</title>
        <description>Morning Pre-Dose Trough FEV1 on Day 30</description>
        <time_frame>Day 30</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MD (PT003)</title>
            <description>GFF MDI 14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Pre-Dose Trough FEV1 on Day 30</title>
          <description>Morning Pre-Dose Trough FEV1 on Day 30</description>
          <population>MITT Population</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.090" lower_limit="0.032" upper_limit="0.148"/>
                    <measurement group_id="O2" value="-0.064" lower_limit="-0.124" upper_limit="-0.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in Inspiratory Capacity (IC) Following the Evening Dose on Day 29</title>
        <description>Peak Change from Baseline in Inspiratory Capacity (IC) following the evening dose on Day 29</description>
        <time_frame>Day 29</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MD (PT003)</title>
            <description>GFF MDI 14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in Inspiratory Capacity (IC) Following the Evening Dose on Day 29</title>
          <description>Peak Change from Baseline in Inspiratory Capacity (IC) following the evening dose on Day 29</description>
          <population>MITT Population</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.486" lower_limit="0.369" upper_limit="0.603"/>
                    <measurement group_id="O2" value="0.105" lower_limit="-0.019" upper_limit="0.229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in IC Following the Morning Dose on Day 29</title>
        <description>Peak Change from Baseline in IC following the morning dose on Day 29</description>
        <time_frame>Day 29</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MD (PT003)</title>
            <description>GFF MDI 14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in IC Following the Morning Dose on Day 29</title>
          <description>Peak Change from Baseline in IC following the morning dose on Day 29</description>
          <population>MITT Population</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.543" lower_limit="0.448" upper_limit="0.639"/>
                    <measurement group_id="O2" value="0.208" lower_limit="0.106" upper_limit="0.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time the subject signed consent up to the follow-up phone call 7-14 days after last dose of study drug.</time_frame>
      <desc>The Safety Population was defined as all subjects who were randomized to treatment regardless and received at least one dose of study treatment. Serious adverse events collected from the time the subject signed consent up to 14 days following the last dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>GFF MDI PT003</title>
          <description>GFF MDI 14.4/9.6 µg</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo MDI</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Sinus Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertenstion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Colin Reisner, MD, FCCP, FAAAAI</name_or_title>
      <organization>Pearl Therapeutics Inc.</organization>
      <phone>650-305-2600</phone>
      <email>creisner@pearltherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

